Authors
Pragya Bhushan Sandilya, Jyotirmoy Dutta, Hemchandra Deka, Jayanta Das, Nithya Sree Pr, Priyam Bharadwaz, Venkata Satish Kumar Mattaparthi, Tukki Sarkar, Sai Balaji Andugulapati, Kandarpa Kumar Saikia, Akhtar Hussain
Published in
Dalton transactions (Cambridge, England : 2003). Nov 04, 2026. Epub Nov 04, 2026.
Abstract
Ferrocene incorporation is widely regarded as an effective strategy for enhancing the biological performance of anticancer metallodrugs owing to its redox activity and favourable lipophilicity. To systematically evaluate this assumption, a series of six phenyl (Ph)- and ferrocenyl (Fc)-substituted terpyridine-Cu(II) mixed-ligand complexes with quinolone antibiotics of the general formula [Cu(R-tpy)(L)]NO3 was investigated, and their anticancer properties were compared across multiple cancer cell lines. In these complexes, R-tpy is either 4'-phenyl-2,2':6',2″-terpyridine (D1-D3) or 4'-ferrocenyl-2,2':6',2″-terpyridine (D4-D6), and L is the monoanion of the quinolone antibiotic levofloxacin (D1, D4), enrofloxacin (D2, D5) or nalidixic acid (D3, D6). Contrary to expectation, the Ph-substituted complexes consistently exhibited superior cytotoxicity and selectivity toward A549, HepG2, and SKOV-3 cells relative to their Fc counterparts, despite the higher lipophilicity of the latter. Detailed mechanistic studies using representative complexes revealed that the lead Ph analogue induced apoptosis, inhibited clonogenic survival, altered cell-cycle progression, and modulated apoptosis-related genes by upregulating p53, p21, and BAX and downregulating BCL-2. In contrast, the Fc analogue exhibited significantly stronger binding to human serum albumin and markedly reduced intracellular Cu accumulation. These findings reveal an unexpected structure-activity relationship (SAR) in which the Ph-substituted complexes exhibit superior anticancer activity despite the greater lipophilicity of their Fc counterparts, with enhanced HSA association and lower intracellular Cu accumulation potentially contributing to the reduced activity of the Fc analogues.
PMID:
42980315
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0